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SUMMARY: Specific immunotherapy (SIT) is frequently used in the treatment of allergic diseases .
However, the mechanisms
by which SIT achieves clinical improvement remained unclear. We decided to study the
in vivo kinetics of this therapy, using
a nuclear medicine approach (leukocytes labelled with 99mTc-HMPAO) in patients on maintenance doses of specific immu-
notherapy with confirmed clinical efficacy .
Material and methods : We studied 13 allergic patients grouped according to different
treatment schedules: subcutaneous
aqueous allergenic extract (3 latex and 2 hymenoptera venom), subcutaneous depot extract (2 house dust mite and 2 pollens),
subcutaneous modified allergens (2 pollens), sublingual extract (2 house dust mites) . The control group included two allergic
patients submitted to subcutaneous injections of bacterial extract (1 patient - positive control), and aqueous solution (1 patient)
.
At the same time that the therapeutic allergen was administered subcutaneously, the autologous labelled white cells were
injected intravenously in a peripheral vein in the contralateral arm. A thoracic dynamic acquisition
of 60 mins, 64x64 matrix,
2 frame/min, in anterior view was performed . Static acquisition for 256x256 matrix, during 5 mins each at 60, 90, 120, 180, 240,
300 and 360 mins after the administration of the radiolabelled leukocytes, in thoracic (anterior and posterior), and abdominal
view were performed . During the examination, the local erythema was monitored . A similar procedure was undertaken for
sublingual administration of immunotherapy .
Results: The inflammatory activity at the site of SIT injection (aqueous depot extract) started
in the first hour and the increa-
se was time related . For modified allergen extract and sublingual SIT the activity was present since the beginning
of the admi-
nistration
. The ascendant lymphatic drainage, which was directed to the homolateral axillary region, to the lymphoid tissue of
the upper mediastinum and to the anterior region of the neck began earlier . Thoracic focalisations were present for all the
patients, whereas bowel focalisations were only observed for the subcutaneous route of administration
. Sublingual SIT did
not induce axillary or intestinal' inflammatory focalisations, even though the patients had swallowed the allergenic extract . The
uptake coefficient in individualized areas corrected to the uptake coefficient background
was also studied .
Conclusions
: For the subcutaneous route of administration, except for gluteraldheyde modified allergen, the local inflam-
matory activity at the allergenic injection site was significantly higher'
in
depth and was time dependent, maintaining activity
even after complete disappearance of the erythema and/or wheat These results express a
prompt inflammatory involvement
of the immune system with this allergenic therapy, which was unexpected until now . We also observed differences concer-
ning allergic diseases, the type of allergenic extracts and routes of administration .
Key-words: Specific immunotherapy -
Subcutaneous immunotherapy - Sublingual immunotherapy - Allergic inflammation -
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INTRODUCTION
P
llergen specific immunotherapy (SIT) and total
avoidance of exposure to allergens, to which
the patient is sensitised, are the only interven-
tions that really influence in the long-term control of
the allergic disease (1, 2)
.
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In fact, it is now obvious that SIT is the only curative
treatment for hymenoptera venom allergy or latex
anaphylaxis, two examples of life-threatening IgE
dependent mechanisms (1-4)
.
A lot of DBPC studies
(double-blind, placebo-controlled) provide longitudi-
nal data on the clinical efficacy of subcutaneous SIT
on mite, pollen, epithelium and some mould species .
For other respiratory allergic diseases such as bron-
chial asthma, allergic rhinitis and conjunctivitis, the
reduction of symptom scores/need for medication
were also observed
(5) .
Allergen vaccines are, in fact, the only treatment that
may affect the natural course of allergic disease, pre-
venting the development of asthma in patients with
allergic rhinitis, reducing the severity of the disease
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and the need for anti-allergic drugs thereby impro-
ving the patient's quality of life (1) . It is also now reco-
gnized that immunotherapy is long-lasting effective
and should be started earlier in the course of the
disease . It has been propose that SIT reduce the risk
of development of new sensitisations (6, 7), but recent
data has not confirmed this protective effect on
monosensitised allergic patients (8) .
There are several factors that are important to the cli-
nical outcome of SIT concerning efficacy and toleran-
ce: the use of premedication, the allergen source, the
purification, the standardization and the stability of
the extract, the pharmaceutical presentation of the
allergen (native or chemically modified ; aqueous or
depot) . The clinical manifestations before and during
the treatment, the route of SIT administration, and the
schedule followed, should also be evaluated (9) .
The aqueous extracts are highly effective, but induce
more side-effects (local and systemic) than depot and
modified vaccines . These have been developed in an
attempt to reduce or remove allergenicity, while pre-
serving or increasing the immunogenicity. Aqueous
subcutaneous SIT is now the gold standard treatment
for hymenoptera venom allergy and depot aeroaller-
gen extracts for respiratory allergy. The use of chemi-
cally modified allergens is not consensual . Although
recent papers demonstrate a clinical benefit with aller-
goid therapy, DBPC studies comparing both extracts
are still missing (10) .
Local immunotherapy is another strategy for allergic
disease treatment . In spite of the therapeutical bene-
fit observed in some studies, there is no consensus on
the use of the nasal, bronchial or oral route of admi-
nistration of SIT (1, 2, 11) . On the other hand, the sub-
lingual-swallowed administration of SIT in higher
doses, which is another type of local immunotherapy,
has an A level evidence-based medicine for seasonal
and perennial allergic rhinitis in adults and seasonal
allergic rhinitis in children (1, 11, 12) .
The clinical efficacy was demonstrated by DBPC study
and later, with the increment in the allergen doses,
the immunological changes were confirmed (12, 13) .
Recent papers have confirmed the long-lasting (14)
clinical efficacy of sublingual administration in a ran-
domised, placebo-controlled, double blind, double-
dummy study (15) .
In spite of the widespread knowledge in the scientific
literature, the mechanism by which SIT achieves cli-
nical improvement remains unclear. For subcuta-
neous immunotherapy the immunomodulation of the
T-cell response is now accepted : immune deviation
(increase in ThO/Th1), Tcell anergy (decrease in
Th2/ThO), or both mechanisms (1) . However, this is
not so linear, because SIT did not induce Th1-type
cytokine-associated pathology in treated respiratory
allergic patients to aeroallergens (16) . There are other
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immunological changes with subcutaneous SIT : the
rise in allergen-blocking IgG, the induction of IgE-
modulating CD8+ T cells, the reduction of mast cells
and eosinophils on the target mucosa, the decrease in
inflammatory mediators (1, 5, 17-21) and a modula-
tion on the inflammatory trafficking cells by reduced
expression on VCAM-1 (22, 23) .
Immune tolerance depends on different mechanisms,
including Tcell anergy, Tcell depletion by apoptosis,
and active immune suppression (24) . One of the target
mechanisms of SIT is the induction of tolerance to aller-
gens to which the patient is sensitised (25) . IL-10 is pro-
bably a relevant cytokine induced by this treatment and
is related to regulatory T cells that actively control or
suppress the function of others cells, generally in an
inhibitory pattern (5, 25) . The changes in microenviron-
ment due to the decrease in histamine and PGE2 mast
cell release and the IL-10 and TGF-_ release by dendritic
cells could deviate the Tcell population pathway in
order to induce T regs and finally a therapeutic toleran-
ce (26). This recent findings agree with what is current-
ly known about the regulation induced by SIT . It is not
credible that it could promote a Th2 / Thl switch (25) .
Much of the knowledge on SIT is based on studies
performed in subcutaneous route of administration,
but increasing data are now available on sublingual
vaccines. The absorption of allergen through the
intact mucosa and the interaction with local dendritic
cells could induce the process and immune-tolerance .
Besides the intrinsic local effect, the swallowed aller-
gen could induce an additional GALT related mecha-
nism (11, 12) . In fact, the first method of sublingual
administration of SIT in which the allergen was spat
out is significantly less effective. Most of the mecha-
nisms and immunological changes that occur with
sublingual administration of high allergen dose have
been recently demonstrated (1, 27-31) .
There is lots of information available on immunomo-
dulation with SIT, but studies on kinetics of SIT admi-
nistration and its immune effects on allergic patients
are still lacking .
The study of M Bagnasco et al. (32) was highly impor-
tant in understanding much of the data . In this study,
the administration of radiolabelled Par-j-1 by 123 1 isoto-
pe to healthy individuals demonstrated the local persis-
tence of the allergen at the sublingual region for a long
period of time . The systemic radioactivity was only pre-
sent after swallowing the allergen . For sublingual SIT it
seems that the allergen is degraded in the gastroenteral
environment and only peptides are absorbed (33) .
There are no similar studies in the literature concerning
the subcutaneous route of administration .
Radiolabelling of blood cells is a nuclear medicine
technique used in the study of inflammatory diseases
such as chronic bowel inflammatory disease (34-37) .
We considered that this kind of methodology could be
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interesting worth investigating further with regards to
an in vivo approach to the study of SIT mechanism of
action and immune response. We expected to study
the migration of autologous peripheral labelled-leu-
kocytes that were reinjected to the site of the allergen
extract administration in allergic patients, and the
other possible resulting events. We think that the bio-
logical response to the therapy can be easily obser-
ved . The site or sites where the immune response
happen and the different times of the response, can
be established. We decided to study the kinetic res-
ponse to SIT in patients with different types of allergy
concerning the severity, the type of allergenic extracts
administered and different routes of administration .
MATERIAL AND METHODS
The Coimbra University Hospitals Ethics Committee
and Research Commission approved the design of
this study protocol and all the volunteer patients
signed an informed consent form according to the
international ethics consensus .
Subjects
13 adult allergic volunteer patients aged 20 to 51 year
old were enrolled for study . All of them were submit-
ted to SIT for at least 2 years and in all of them the cli-
nical efficacy was demonstrated by complete remis-
sion of symptoms, the absence of medication with
regular anti-allergic drugs, reduction of skin reactivity
to allergens and reduction of serum specific IgE . In
patients with previous anaphylaxis, the absence of
allergic reactivity after the beginning of treatment
was confirmed by challenge tests or immunoblotting
studies .
The patients were selected according to the different
allergenic extracts and routes of administration of SIT,
including :




2 patients - hymenoptera venom, honeybee venom
extract ;
• 3 patients - latex extract .
- Depot subcutaneous allergenic extract (for respirato-
ry allergy) :
• 2 patients - Dermatophagoides pteronyssinus extract ;
• 2 patients - grass pollen extract .
Modified subcutaneous allergenic extract (for respi-
ratory allergy) :
• 1 patient - grass pollen extract;
• 1 patient - Parietaria judaica extract .
Sublingual allergenic extract (for respiratory allergy) :
• 2 patients - Dermatophagoides pteronyssinus extract .
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Dermatophagoides pteronyssinus allergic patients
(bronchial asthma and rhinitis) not submitted to SIT
were studied as a control group .
None of the patients had other clinical disorders,
namely inflammatory diseases . All the female
patients were submitted to a pregnancy test on the
day of the study to exclude pregnancy .
All the studies were performed under strict hospital
medical care surveillance, in the day of SIT administra-
tion, according to each individual schedule of treatment .
Methods
∎ Technetium -99m hexamethylpropyleneamineoxime
leukocyte labelling (99mTC-HMPAO) : The white blood
cells labelling process with 99mTC-HMPAO was per-
formed according to the standard University Hospital
Nuclear Medicine Department protocol, based on the
technique described by Peters et al. (34) . 42 ml of the
patient's blood was collected from peripheral vein
with a 60 ml plastic syringe, containing 6 ml of acid-
citrate-dextrose (ACD) plus 6 ml of hydroxy-ethil-star-
ch (HES) at 6% .
The ACD anticoagulant prevents cells from sticking to
the plastic wall of tubes and the HES accelerates ery-
throcyte sedimentation by affecting the charge of the
sialic acid groups on the outer membrane of the red
blood cell . This blood in the syringe was maintained
in a vertical position for 30 mins in order to allow ery-
throcyte sedimentation . A second 10 ml syringe of
blood was sampled with 1ml of ACD . This blood was
centrifuged at 2 000 g for 10 min in order to obtain
cell-free plasma (CFP) .
After 30 mins of blood syringe sedimentation, the
supernatant was centrifuged at 150 g for 5 min and the
supernatant, platelet rich plasma (PRP) was dischar-
ged. The leukocyte pellet was resuspended in 0 .6 ml of
cell free plasma and labeled with 99mTC-HMPAO
(Ceretec®, Amersham, UK) . For the leukocyte labeling
procedure, the HMPAO must be labeled first . For this
purpose, a 1110 MBq in 5 ml of saline of 99mTc fresh-
ly eluted was added to a kit of HMPAO that contained
0.5 mg of exametazime, 7.6 mg of SnCl 2 and 4.5 mg of
NaCl according to the manufacturer's indications. 3 ml
of this 99mTc-HMPAO was added to the leukocytes
resuspended in cell free plasma, and the mixture was
maintained at room temperature for incubation, for 10
min, in order to label the leukocytes . After this time, 10
ml of PRP was added to the leukocytes in order to stop
the labeling procedure, and the mixture was centrifu-
ged at 150g for 5 min .
After centrifugation, the supernatant was removed
and discharged and the labeled leukocyte pellet was
resuspended in 5 ml of CFP, counted and re-injected
into the patients .
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The labeling yield ranged between 50% and 75%, as
normally described .
The effective dose-equivalent for this examination
was 0.021 mSv/MBq (38, 39) .
•
	
Allergenic therapeutic extract : The allergenic extra-
cts administered were from ALK-Abe116 (Spain) for all
the patients except for modified subcutaneous aller-
genic extract . These extracts were glutaraldehyde
modified grass pollen (Bial/Aristegui- Spain) and
depigmented Parietaria judaica pollen (Leti- Spain)
.
All the patients were submitted to the maintenance
dose according to the individual schedule .
One allergic patient of the control group was submitted
to a 0.5cc subcutaneous phenol aqueous injection sup-
plied by ALK-Abe116 (Spain), and the other patient was
submitted to a 0.5cc subcutaneous injection of a bacte-
rial extract (RibomunylTM, Pierre Fabre Medicament,
France: ribosomal fractions of Klebsiella pneumoniae,
Streptococcus pneumoniae, Streptococcus pyogenes,
Haemophilus influenzae and the membrane fraction of
Klebsiella pneumoniae), an nonspecific immunostimu-
lant agent of IgG production .
• Administration procedures : Patients were lying
supine under the gamma camera
. A humeral vein was
catheterised to permit the reinjection of labeled auto-
logous leukocytes
. The allergen extract was adminis-
tered subcutaneously, according to the usual method,
in the contra lateral arm
. Both injections were given at
the same time, simultaneously with the scintigraphic
acquisitions .
The 2 allergic patients under sublingual SIT were also
lying supine under the gamma camera at the begin-
ning of the study
. The drops of the allergenic extract
were administered at the same time as the reinjection
of the labeled autologous leukocytes in the humeral
vein . Three minutes later, the-patients swallowed the
allergen extract .
For the control group the same procedure was adop-
ted. The study was performed under the close super-
vision of allergist and nuclear medicine specialists .
• Scintigraphic acquisitions (table 1) : Scintigraphic
studies were performed on a large field of view digi-
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ced with a Camstar acquisition unit and an eNTEGRA
processing unit), equipped with a parallel low-energy
general purpose collimator .
A dynamic acquisition was obtained in anterior view
at thoracic and neck level for 64x64 matrix for 60
minutes (120 frames x 30 seconds) followed by static
images at 60, 90, 120, 180, 240, 300 and 360 mins after
administration of the radiolabeled leukocytes and the
allergen for 256x256 matrix and for 5 mins each .
These static images were obtained in anterior and
posterior views at thoracic level and anterior views at
abdominal projection .
During the acquisitions, the visualized area was kept
close to the gamma-camera collimator, and the patients
were not allowed to move any part of the body, in order
to maintain the geometry of the projections .
Throughout the acquisitions, the erythema and the
wheal at the site of SIT administration were controlled
.
For quantitative results, the procedure was different
according to the type of image . For the dynamic tho-
racic images, regions of interest (ROls) were drawn
at SIT administration, background area (muscle),
and for possible focalisations (cervical and axillary
areas and thorax)
. For the thoracic static views, an
image corresponding to the geometric mean bet-
ween anterior and posterior views was calculated,
and ROls were drawn at thoracic locations . For the
static anterior abdominal views, ROls were drawn
over each location .
For each ROI the total counts, average counts per
pixel and maximum counts were obtained, and
decayed was corrected. With these values, uptake
coefficients were calculated by the ratio between the
maximum count rate at the target ROI and average
counts at the background ROI . In order to normalise
and to help with the interpretation of the results an
uptake coefficient of the background ROI was calcu-
lated and subtracted from the uptake coefficient of
the target ROls .
∎ Data analysis : The clinical pattern, allergen extra-
ct and route of administration were analysed indivi-
dually and the different groups of patients were
compared .
The statistical analysis was performed by descripti-
ve analysis .
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There were no adverse events caused by radiolabeled
autologous cells reinjection or allergenic therapeutic
extract administration .
Clinical and allergenic therapeutic extract aspects are
shown in table 2 and 3 .
After scintigraphic processing, the ROI value was
obtained at the site of SIT administration, thoracic,
axillary and cervical area, abdominal focalizations
and ROI background . We also calculated the corrected
uptake coefficient (maximum count at the site of SIT
ROI over average counts at the background ROI) at
different focalisations at different times .
The uptake coefficients for the different focalisations
on analysis are shown in Figs . 1-5 .
We did not consider the scintigraphic acquisitions at
the site of the allergenic injection (patient 1, 2 and 9)
and the axillary area (patient 1) due to technical pro-
blems .
The inflammatory activity started early in patients
treated with aqueous allergenic extract for anaphy-
laxis than for in patients treated with depot extracts
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for other diseases (latex : 20-35 mins; hymenoptera
venom : 15 mins; grass pollen : 25 and 30 mins; mites:
25 and 45 mins) .
For sublingual allergenic extracts the inflammatory
activity started promptly (at 5 mins) with a rapid
increase that persisted during the study .
In patients submitted to allergoid, the inflammatory
activity at site of administration of the extract started
in the first minutes, although with a different pattern .
In the allergic patient submitted to saline subcuta-
neous injection, we observed low values of activity at
the site of administration, probably related with an
irritative effect caused by phenol used as preservati-
ve. This observation confirms the sensitivity of the
laboratory procedure. No other focalisations were
observed during the study .
The control patient submitted to bacterial injection sho-
wed inflammatory activity at 10 minutes with an increa-
se that was time related . We also observed activity in
the axillary, the cervical and the thoracic areas, but with
no focalisations at the bowel region, Fig . 6.
The inflammatory activity at the axillary and the cer-
vical areas was present from the beginning of the
Figures 1: Uptake coefficient corrected o
allergenic extract local administration .
Figures 2 : Uptake coefficient corrected





Table 2 : Clinical aspects of patients sample .
Disease: A= anaphylaxis ; BA+AR= bronchial asthma+allergic rhinitis .
Allergen : L=latex ; HV= hymenoptera venom (honeybee) ; GP= grass pollen ; Dp= Dermatophagoides pteronyssinus
judaica
SIT route : sc= subcutaneous
; sl= sublingual




volume in ml administrated of the maintenance dose . Patients 12 and 13 are submitted to 5 drops
SIT dose: quantity of allergen in µg protein
Administered activity : MBq
Table 3 : Control group . Clinical aspects
Disease
: BA+AR= bronchial asthma+allergic rhinitis .
Allergen : Dp= Dermatophagoides pteronyssinus






Disease Allergen Injection Volume(cc) Administered
activity
1 F 41 20 BA+AR Dp saline 0.50 306.4

















1 F 34 7 A L sc 6 0.35 0.35 272.0
2 F 39 6 A L sc 5 0.35 0.35 240.5
3 F 28 7 A L sc 5 0.35 0.35 149.6
4 M 49 5 A HV sc 4 1 .0 100 67.7
5 F 37 4 A HV sc 4 1 .0 100 316.3
6 F 53 14 BA+AR GP sc depot 4 0.60 1 .5 337.2
7 F 24 10 BA+AR GP sc depot 4 0.60 1 .5 255.5
8 M 22 12 BA+AR Dp sc depot 4 0.60 3.6 91 .8
9 F 51 30 BA+AR Dp sc depot 5 0.60 3.6 170.3
10 M 33 28 BA+AR GP sc allergoide 5 0.70 36.72 476.7
11 F 49 34 BA+AR Pj sc allergoide 3 0.50 12.0 132.7
12 M 20 10 BA+AR Dp sl aqueous 3 5* 1 .2 126.3
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acquisitions for the subcutaneous allergenic extracts .
There was a stabilization of the uptake coefficient
values at 180 minutes. There were no focalisations at
the axillary areas after sublingual immunotherapy .
The high-labelled cell circulating pool could affect the
interpretation of focalisations in the lung area in the
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Figures 3 : Uptake coefficient corrected
cervical area focalisations .
igures 4 : Uptake coefficient corrected
lung focalisations .
Figures 5: Uptake coefficient corrected o
gut focalisations .
after 60 minutes after the injection, even though they
were observed earlier . There were no significant dif-
ferences among the different groups .
Focalisations at the abdomen acquisition views were
observed in all the patients submitted to subcuta-
neous SIT. We only considered ROls till 240 minutes .
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tic/gall bladder excretion of the product. No bowel acti-
vity was observed in patients on SLIT treatment .
There were other focalisations such as supraster-
num and anterior mediastinum with high inflamma-
tory activity, but we decided not to consider these
areas because they were sites of vascular confluen-
ce. Bone marrow was another site of intense activi-
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Figures 6 : Uptake coefficient corrected/time
for the ROls of the active control patient sub-
mitted to bacterial extract .
Figures 7: Patient 1 study, dynamic and sta-
tic acquiitions . Inflammatory activity at 25,
90 120, 180, 240 min .) .
Figures 8 : Patient 12 study, dynamic and
static acquisitions . Inflammatory activity at
240 min .
ty, higher than that usually observed by this tech-
nique .
Distinct ROI count profiles were obtained with the dif-
ferent routes of administration and with the different
allergenic extracts but all of them induced a time-
dependent global inflammatory activation at sites
related with the immune system (Fig. 7-10) .








i 60 90 120 150 80 210 2 0











Concerning depot allergenic extracts, we did not
observe differences between pollen and mite
allergic patients .
For mite allergic patients, there were the same
obvious differences concerning SIT routes of
extract administration . The sublingual immuno-
therapy induced an early potent activity with
higher uptake coefficient ROI values than the
depot extracts, at site of the allergic extract admi-
nistration .
The inflammatory activity at the local of SIT admi-
nistration was greater than the erythema area
involving the deeper layers and persisted even
after local inflammatory signs disappeared .
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DISCUSSION
In this study we decided not to label the allergen used,
because it was only possible to make a linkage between
an allergenic epitope and the radiolabel-drug, excluding
the other epitopes. The decision to use the common
administration of SIT seemed to be the procedure that
minimised the error factors in the understanding of this
therapy dynamics. The technique is now a routine pro-
cedure for analogous inflammatory pathologies . The
risks are minimal, the radioactive burden is low, and the
body-absorbed dose (effective dose) corresponds to
about 3mSv, which is similar to one year of natural
exposure in the continental area of Portugal .
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Our first attempt was to study the local inflammation
related to SIT administration . The activity observed in
other areas and the speed of occurrence was a sur-
prising result. Even in patients with excellent clinical
response to immunotherapy, the administration of
specific allergen resulted in a local inflammatory res-
ponse that ranged from minimal intensity to erythe-
ma and/or wheal . The intensity of inflammation was
higher for aqueous extract administrations in patients
with the most severe allergic diseases . However, it
was not related with clinical signs of inflammation at
the site of administration . The allergoids were related
with lower inflammatory activity when compared
with depot extracts, as expected, according to the cli-
nical knowledge (40) . In the 2 patients submitted to
sublingual extracts the beginning of the radioactivity
was faster, with no signs of local effects . There was a
minimal activity in the control patient who was sub-
mitted to phenol-saline injection, which is usually
used to dilute the extracts . We considered that this
reaction was related to phenol, which is a nonspecific
irritant used as a preservative. This observation
confirmed the sensitivity of the technique . The other
control patient that was submitted to an injection of
bacterial derived fragments, also revealed activity
according to the expected IgG dependent mechanism
of action of this immune-stimulant (41) .
In the first minutes ascending drainage directed to the
homolateral axillary area was induced by subcuta-
neous SIT. Cervical and superior mediastinum lym-
phoid tissues were the next structures involved . The
late static acquisitions showed global activation on
focalisations related to the immune system : lymphoid
tissue neck/cervical, suprasternum, mediastinum,
lung, gut and bone marrow. The early involvement of
the central lymphoid structures was an unexpected
finding. The maximum ROI values were increased
even when the radionuclide was eliminated through
urine and the half time was reached . This could reflect
the magnitude of the therapeutical allergen mecha-
nism of restimulation and immune-tolerance .
Concerning the sublingual immunotherapy the activi-
ty was reached faster than for subcutaneous SIT.
There was an obvious difference in the inflammatory
activity profile comparing these two types of immu-
notherapy. The most intense ROI values were achie-
ved at the cervical lymphoid tissue, as expected .
There was no activity in the axillar and the abdominal
area, compared with depot extract. This data could
explain the need for daily or three times a week admi-
nistration of sublingual SIT in order to promote fre-
quent stimulation of the immune system .
The allergoid extracts also induced inflammatory acti-
vity when compared with depot pollen extracts
. There
were obvious differences in local activity between
both. Our results could deflect some criticism of lot of
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authors who reject the use of polymerised vaccines or
chemically modified allergens .
This technique did not allow labelling specific circula-
ting peripheral cells . The pellet resulting from a blood
sample contains all the lineages of white blood cells.
At first, the lymphocytes seemed to be the only cells
responsible for the local and global events in the
study. However, we must reflect on all the knowledge
about SIT, inflammation and immune response avai-
lable till now .
Dendritc cells (DC) have been a matter of exhaustive
study and seem to be a nuclear target of inflammation
and immune tolerance . The professional APC are divi-
ded into two major systems : DC, including blood and
tissue DC as well as epidermal Langerhans cells (LC),
and
the monocyte/macrophage system (42) .
Concerning DC there are two different subsets : DC1 or
myeloid DC, and DC2 or lymphoid/plasmocytoid DC
(42, 43)
. DC2 are mainly found in thymic medulla, ton-
sils and in T cell areas of secondary lymphoid organs,
whereas DC1 are located outside the T cell areas . DC2
are unable to internalise foreign antigen (42) . On the
other hand, DC1 could traffic from the blood to the
peripheral tissue to capture foreign antigens, may
migrate to the draining lymphoid organs in order to
prime T cells towards Th1 or Th2 cytokine profile (26,
43, 44). Under appropriate stimulus peripheral blood
monocytes could differentiate to DC1 (42) .
Langerhans cells belong to the DC1 system and are
relevant in the skin . After local inflammatory stimulus
the monocyte-chemoattractant protein (MCP) induces
recruitment of LC progenitors from the bone marrow,
migration to the skin and in the skin, and migration to
peripheral lymph nodes (43) . It is now well established
that IL-10 DC release is an important factor of immune
tolerance promoting Tregs lymphocytes (25, 26, 45)
.
The DC family of oral mucosa is different from that of
the skin LC family. The oral microenvironment and TGF-
R
are relevant as well as IL-10 (43) . They also presented
increased expression of FccRl on their surface, which
was partially occupied by IgE molecules (43)
.
The linka-
ge of allergens to the FcERI receptor contributes to tole-
rance by an IL-10 dependent mechanism (42, 43)
.
According to our results these data could be explai-
ned by the following hypothesis : The subcutaneous
allergenic extract induced activation of LC, recruit-
ment of other circulating DC/monocytes ; migration to
lymphoid areas ; cooperation with DC2 and finally
Tregs induced by IL-10 and tolerance towards sensiti-
sed allergens . The systemic activation of areas related
with the immune system could support the global
imunomodulation of SIT.
Large amounts of allergen are administered by sub-
lingual SIT route in an area with close proximity to
lymphoid organs such as the lingual amygdale . It is
possible that DC could initiate the process as occurs
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in the skin . However the presence of lymph nodes
with other populations of DC (DC2) could lead to a
saturation of activity of DC1 and the inability to cause
an intense systemic inflammatory activity. The indu-
ced tolerance and the efficacy of this therapy are,
consequently less intense and require frequent stimu-
lation and higher allergen doses. On the other hand,
the swallowed allergen could interact with gastroin-
testinal mucosa and promote additional tolerance
mechanism, mediated by TGF-(3 and Th3 regulatory
cells (43, 45) .
Our results showed a real systemic effect of SIT, rela-
ted to focalisations on immune system dependence .
The inflammatory activity began quicker than we
expected and there were obvious differences concer-
ning the different extracts. There seems to exist an
obvious difference between the kinetic of sublingual
and subcutaneous routes of administration . Aqueous
allergenic extracts induce more intense and global
systemic inflammatory activity than depot extracts
and ultimately the allergoid extracts .
In the future it will be important to study the kine-
tic/dynamic of the built-phase of SIT in animal models
in order to understand how the tolerance/immuno-
modulation process occur throughout the treatment .
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AVOIDING PEANUTS MAY RESULT IN RECURRENCE OF ALLERGY. FROM THE
JOURNAL OF ALLERGY & CLINICAL IMMUNOLOGY
Children who keep avoiding peanuts after they outgrow their peanut
allergy -h 3
rat their peanut allergy will return, according to a study in the November 2004 Journal
;3f_Alle
I 'Immunology (JACI)
. The JACI is the peer-reviewed journal of the American Academy of
AI11
*>k &'Immunology (AAAAI) .
,study,
David M . Fliescher, MD, Johns Hopkins University School of Medicine, and
colleagie .
ants who had previously outgrown their peanut allergy
. They sought to determine the percefda
who reacquire peanut allergy later
; identify any risk factors for recurrent peanut allergy, and'de
c -+'eeE emendations for treating patients who have outgrown peanut allergy
.
on dtlestionnaire results, repeat peanut-specific IgE levels, and repeat food challenges,
the reseer6
ti' that patients who have outgrown their peanut allergy have approximately an 8% chance of ft
r




study's results, researchers recommend that patients eat concentrated forms
of'penut of 1




also recommended that patients and families who
rarely eat peanuts or eat then~4n f"it
i'4 mer outgrowing their allergy should continue to
carry epinephrine at all times .
I is the largest professional medical specialty organization in the United States representing
allergists, ast ' ;
atti&ts,iclinical immunologists, allied health professionals and others with a special interest
in the reseami and w_ ,
of&Ifergicdisease
. Established in 1943, the AAAAI has nearly 6,000 members in the United
States, Canada ar+d `
tries . The AAAAI serves as an advocate to the public by providing educational information
through its Web l iatY
.',
saaai,org or the toll-free physician referral and information line at 1(800) 822-2762
.
ffIRIS NOTE: This study was published in the peer-reviewed, scientific journal of the American Academy
: of Alte
& immunology, but does not necessarily reflect the policies or the opinions of the Academy
. To receive a yL
sleasl~ contact John Gardner ( j
gardner@aaaai .org) at (414) 272-6071
. For more information and mess tiA
past
JACI news releases, visit the Media Center of the AAAAI Web, site,
www.aaaai .org .
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